Nov 5 (Reuters) - Theratechnologies Inc TH.TO :
* FDA APPROVES NOVEL SINGLE-VIAL FORMULATION OF EGRIFTA®
* THERATECHNOLOGIES INC - FDA APPROVES EGRIFTA FOR TREATMENT OF EXCESS ABDOMINAL VISCERAL ADIPOSE TISSUE IN HIV-INFECTED PATIENTS WITH LIPODYSTROPHY